Robert Jech

List of Publications by Year
in descending order

164 papers	5,162 citations	109137 35 h-index	114278 63 g-index
168 all docs	168 docs citations	168 times ranked	6184 citing authors

#	Article	IF	Citations
1	Transcranial Magnetic Stimulation during Positron Emission Tomography: A New Method for Studying Connectivity of the Human Cerebral Cortex. Journal of Neuroscience, 1997, 17, 3178-3184.	1.7	657
2	Dose-Dependent Reduction of Cerebral Blood Flow During Rapid-Rate Transcranial Magnetic Stimulation of the Human Sensorimotor Cortex. Journal of Neurophysiology, 1998, 79, 1102-1107.	0.9	224
3	Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain, 2010, 133, 701-712.	3.7	212
4	Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurology, The, 2015, 14, 992-1001.	4.9	174
5	Functional magnetic resonance imaging during deep brain stimulation: A pilot study in four patients with Parkinson's disease. Movement Disorders, 2001, 16, 1126-1132.	2.2	153
6	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 2017, 45, 13-20.	1.1	149
7	Monogenic variants in dystonia: an exome-wide sequencing study. Lancet Neurology, The, 2020, 19, 908-918.	4.9	139
8	Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Movement Disorders, 2005, 20, 937-944.	2.2	113
9	Sleep Disturbances and Hypocretin Deficiency in Niemann-Pick Disease Type C. Sleep, 2003, 26, 427-430.	0.6	104
10	<scp>JuSpace</scp>: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps. Human Brain Mapping, 2021, 42, 555-566.	1.9	95
11	Investigation of non-linear properties of multichannel EEG in the early stages of Parkinson's disease. Clinical Neurophysiology, 2001, 112, 38-45.	0.7	86
12	Efficacy and safety of a standardised 500 unit dose of Dysport Â® (Clostridium botulinum toxin type A) Tj ETQq0 0 0 rgBT /Overlock 10 T multicentre, randomised, double-blind, placebo-controlled, parallel group study. Journal of Neurology, 2001, 248, 1073-1078.	1.8	79
13	Efficacy and safety of abobotulinumtoxinA in spastic lower limb. Neurology, 2017, 89, 2245-2253.	1.5	79
14	Lossâ€ofâ€Function Variants in <scp>HOPS</scp> Complex Genes <scp>VPS16</scp> and <scp>VPS41</scp> Cause Early Onset Dystonia Associated with Lysosomal Abnormalities. Annals of Neurology, 2020, 88, 867-877.	2.8	70
15	Performance comparison of extracellular spike sorting algorithms for single-channel recordings. Journal of Neuroscience Methods, 2012, 203, 369-376.	1.3	64
16	De novo variants in neurodevelopmental disordersâ€"experiences from a tertiary care center. Clinical Genetics, 2021, 100, 14-28.	1.0	64
17	Disorders of Balance and Gait in Essential Tremor Are Associated with Midline Tremor and Age. Cerebellum, 2013, 12, 27-34.	1.4	61
18	Paroxysmal exercise-induced dystonia within the phenotypic spectrum ofECHS1deficiency. Movement Disorders, 2016, 31, 1041-1048.	2.2	58

#	Article	IF	Citations
19	Deep brain stimulation of the subthalamic nucleus affects resting EEG and visual evoked potentials in Parkinson's disease. Clinical Neurophysiology, 2006, 117, 1017-1028.	0.7	55
20	Validity of primary motor area localization with fMRI versus electric cortical stimulation: A comparative study. Acta Neurochirurgica, 2009, 151, 1071-1080.	0.9	55
21	The Subthalamic Microlesion Story in Parkinson's Disease: Electrode Insertion-Related Motor Improvement with Relative Cortico-Subcortical Hypoactivation in fMRI. PLoS ONE, 2012, 7, e49056.	1.1	51
22	Separate neural representations of depression, anxiety and apathy in Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 12164.	1.6	49
23	Distinct populations of neurons respond to emotional valence and arousal in the human subthalamic nucleus. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3116-3121.	3.3	48
24	Resting-state functional magnetic resonance imaging of the subthalamic microlesion and stimulation effects in Parkinson's disease: Indications of a principal role of the brainstem. NeuroImage: Clinical, 2015, 9, 264-274.	1.4	46
25	Efficacy of repetitive transcranial magnetic stimulation for the treatment of refractory chronic tinnitus: a randomized, placebo controlled study. Neuroendocrinology Letters, 2010, 31, 238-49.	0.2	46
26	Pathogenic SPTBN1 variants cause an autosomal dominant neurodevelopmental syndrome. Nature Genetics, 2021, 53, 1006-1021.	9.4	44
27	MR relaxometry in Huntington's disease: Correlation between imaging, genetic and clinical parameters. Journal of the Neurological Sciences, 2007, 263, 20-25.	0.3	43
28	Deep brain stimulation in acute management of status dystonicus. Movement Disorders, 2009, 24, 2291-2292.	2.2	43
29	Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease. NeuroImage: Clinical, 2018, 19, 1025-1035.	1.4	43
30	The sensitivity of ECG contamination to surgical implantation site in brain computer interfaces. Brain Stimulation, 2021, 14, 1301-1306.	0.7	43
31	Variation of selective gray and white matter atrophy in Huntington's disease. Movement Disorders, 2007, 22, 1783-1789.	2.2	42
32	Subthalamic nucleus stimulation affects incentive salience attribution in Parkinson's disease. Movement Disorders, 2011, 26, 2260-2266.	2.2	42
33	KMT2B rare missense variants in generalized dystonia. Movement Disorders, 2017, 32, 1087-1091.	2.2	42
34	Repetitive TMS of the somatosensory cortex improves writer's cramp and enhances cortical activity. Neuroendocrinology Letters, 2010, 31, 73-86.	0.2	42
35	Sleep disturbances in untreated Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 2254-2259.	1.8	40
36	Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease. Movement Disorders, 2000, 15, 734-735.	2.2	38

#	Article	IF	Citations
37	Cumulative blood oxygenation-level-dependent signal changes support the â€˜time accumulatorâ€™ hypothesis. NeuroReport, 2005, 16, 1467-1471.	0.6	37
38	Molecular diversity of combined and complex dystonia: insights from diagnostic exome sequencing. Neurogenetics, 2017, 18, 195-205.	0.7	37
39	VIM thalamic stimulation for tremor in a patient with IgM paraproteinaemic demyelinating neuropathy. Movement Disorders, 2003, 18, 1192-1195.	2.2	36
40	Effects of Ropinirole Prolonged-Release on Sleep Disturbances and Daytime Sleepiness in Parkinson Disease. Clinical Neuropharmacology, 2010, 33, 186-190.	0.2	36
41	Grooved Pegboard Predicates More of Cognitive Than Motor Involvement in Parkinsonâ€™s Disease. Assessment, 2014, 21, 723-730.	1.9	35
42	Pallidal stimulation in siblings with pantothenate kinaseâ€associated neurodegeneration: Fourâ€year followâ€up. Movement Disorders, 2011, 26, 184-187.	2.2	34
43	Levodopa increases functional connectivity in the cerebellum and brainstem in Parkinsonâ€™s disease. Brain, 2013, 136, e234-e234.	3.7	34
44	Abnormal Activity in the Precuneus during Time Perception in Parkinson's Disease: An fMRI Study. PLoS ONE, 2012, 7, e29635.	1.1	34
45	Predicting Falls in Parkinson Disease: What Is the Value of Instrumented Testing in OFF Medication State?. PLoS ONE, 2015, 10, e0139849.	1.1	34
46	Increase in body weight is a non-motor side effect of deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neuroendocrinology Letters, 2007, 28, 21-5.	0.2	34
47	Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. Journal of Neural Transmission, 2000, 107, 1297-1306.	1.4	32
48	Tests of manual dexterity and speed in Parkinsonâ€™s disease: Not all measure the same. Parkinsonism and Related Disorders, 2016, 28, 118-123.	1.1	32
49	Mild cognitive impairment disrupts attention network connectivity in Parkinson's disease: A combined multimodal MRI and meta-analytical study. Neuropsychologia, 2018, 112, 105-115.	0.7	31
50	Electromagnetic field of mobile phones affects visual event related potential in patients with narcolepsy. Bioelectromagnetics, 2001, 22, 519-528.	0.9	30
51	General and selective brain connectivity alterations in essential tremor: A resting state fMRI study. NeuroImage: Clinical, 2017, 16, 468-476.	1.4	29
52	Hormonal regulators of food intake and weight gain in Parkinson's disease after subthalamic nucleus stimulation. Neuroendocrinology Letters, 2011, 32, 437-41.	0.2	29
53	KMT2B Is Selectively Required for Neuronal Transdifferentiation, and Its Loss Exposes Dystonia Candidate Genes. Cell Reports, 2018, 25, 988-1001.	2.9	28
54	Fast vergence eye movements are disrupted in Parkinson's disease: A video-oculography study. Parkinsonism and Related Disorders, 2015, 21, 797-799.	1.1	27

#	Article	IF	Citations
55	Weight Gain Is Associated with Medial Contact Site of Subthalamic Stimulation in Parkinson's Disease. PLoS ONE, 2012, 7, e38020.	1.1	27
56	Reply: Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion. Movement Disorders, 2006, 21, 2268-2268.	2.2	24
57	Abnormal corticospinal tract modulation of the soleus H reflex in patients with pure spastic paraparesis. Neuroscience Letters, 2008, 437, 15-19.	1.0	24
58	Concomitant Medication Usage with <scp>Levodopaâ€Carbidopa</scp> Intestinal Gel: Results from the <scp>COSMOS</scp> Study. Movement Disorders, 2021, 36, 1853-1862.	2.2	24
59	Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data. Dementia and Geriatric Cognitive Disorders, 2015, 39, 303-311.	0.7	23
60	Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion. Movement Disorders, 2005, 20, 759-762.	2.2	21
61	Colour discrimination impairment is not a reliable early marker of Parkinson's disease. Journal of Neurology, 2001, 248, 975-978.	1.8	20
62	DYT 6-A novel THAP1 mutation with excellent effect on pallidal DBS. Movement Disorders, 2011, 26, 924-925.	2.2	20
63	Chronic stress-like syndrome as a consequence of medial site subthalamic stimulation in Parkinson's disease. Psychoneuroendocrinology, 2015, 52, 302-310.	1.3	20
64	Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease. European Neuropsychopharmacology, 2019, 29, 1258-1272.	0.3	20
65	Prevalence and evolution of spasticity in patients suffering from firstâ€ever stroke with carotid origin: a prospective, longitudinal study. European Journal of Neurology, 2019, 26, 880-886.	1.7	20
66	Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinaseâ€“Associated Neurodegeneration. Movement Disorders, 2021, 36, 1342-1352.	2.2	20
67	Memory impairment in Parkinsonâ€™s disease: The retrieval versus associative deficit hypothesis revisited and reconciled.. Neuropsychology, 2019, 33, 391-405.	1.0	20
68	Correlation between Relaxometry and Diffusion Tensor Imaging in the Globus Pallidus of Huntingtonâ€™s Disease Patients. PLoS ONE, 2015, 10, e0118907.	1.1	20
69	Frontal Assessment Battery in Parkinsonâ€™s Disease: Validity and Morphological Correlates. Journal of the International Neuropsychological Society, 2017, 23, 675-684.	1.2	19
70	The Diagnostic Accuracy of Parkinson's Disease Mild Cognitive Impairment Battery Using the Movement Disorder Society Task Force Criteria. Movement Disorders Clinical Practice, 2017, 4, 237-244.	0.8	19
71	Sex, Food and Threat: Startling Changes after Subthalamic Stimulation in Parkinson's Disease. Brain Stimulation, 2013, 6, 740-745.	0.7	18
72	Frequency-phase analysis of resting-state functional MRI. Scientific Reports, 2017, 7, 43743.	1.6	18

#	Article	IF	Citations
73	Methods for automatic detection of artifacts in microelectrode recordings. Journal of Neuroscience Methods, 2017, 290, 39-51.	1.3	18
74	Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinsonâ€™s disease patients. Scientific Reports, 2018, 8, 14328.	1.6	18
75	Regional gray matter changes and age predict individual treatment response in Parkinson's disease. NeuroImage: Clinical, 2019, 21, 101636.	1.4	18
76	Differential effects of deep brain stimulation and levodopa on brain activity in Parkinsonâ€™s disease. Brain Communications, 2020, 2, fcaa005.	1.5	18
77	Blood DNA methylation provides an accurate biomarker of KMT2B-related dystonia and predicts onset. Brain, 2022, 145, 644-654.	3.7	18
78	A Comparative Study of Tower of London Scoring Systems and Normative Data. Archives of Clinical Neuropsychology, 2017, 32, 328-338.	0.3	17
79	Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial. PM and R, 2017, 9, 1181-1190.	0.9	17
80	Recessive variants in ZNF142 cause a complex neurodevelopmental disorder with intellectual disability, speech impairment, seizures, and dystonia. Genetics in Medicine, 2019, 21, 2532-2542.	1.1	17
81	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	1.1	17
82	Beneficial effect of deep brain stimulation of GPi in a patient with dystoniaâ€deafness phenotype. Movement Disorders, 2009, 24, 465-466.	2.2	16
83	Cortical pattern of complex but not simple movements is affected in writerâ€™s cramp: A parametric event-related fMRI study. Clinical Neurophysiology, 2012, 123, 755-763.	0.7	16
84	A unique de novo gain-of-function variant inCAMK4associated with intellectual disability and hyperkinetic movement disorder. Journal of Physical Education and Sports Management, 2018, 4, a003293.	0.5	16
85	Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinsonâ€™s Disease. Cerebellum, 2019, 18, 212-224.	1.4	16
86	Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinsonâ€™s Disease and Cross-Cultural Comparison. Assessment, 2020, 27, 1960-1970.	1.9	16
87	Spatial and nonspatial memory involvement in myasthenia gravis. Journal of Neurology, 1997, 244, 529-532.	1.8	15
88	Decrease in Blood Cortisol Corresponds to Weight Gain following Deep Brain Stimulation of the Subthalamic Nucleus in Parkinsonâ€™s Disease. Stereotactic and Functional Neurosurgery, 2012, 90, 410-411.	0.8	15
89	Wrapper feature selection for small sample size data driven by complete error estimates. Computer Methods and Programs in Biomedicine, 2012, 108, 138-150.	2.6	15
90	Eye Movements in Ephedrone-Induced Parkinsonism. PLoS ONE, 2014, 9, e104784.	1.1	15

#	Article	IF	Citations
91	7â€Tesla <scp>Magnetic Resonance Imaging</scp> for Brain Iron Quantification in Homozygous and Heterozygous <scp>PANK</scp>2 Mutation Carriers. Movement Disorders Clinical Practice, 2014, 1, 329-335.	0.8	15
92	Comparative analysis of speech impairment and upper limb motor dysfunction in Parkinsonâ€™s disease. Journal of Neural Transmission, 2017, 124, 463-470.	1.4	15
93	Test the Best: Classification Accuracies of Four Cognitive Rating Scales for Parkinsonâ€™s Disease Mild Cognitive Impairment. Archives of Clinical Neuropsychology, 2020, 35, 1069-1077.	0.3	15
94	Clinically relevant copy-number variants in exome sequencing data of patients with dystonia. Parkinsonism and Related Disorders, 2021, 84, 129-134.	1.1	15
95	Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinsonâ€™s disease?. Journal of Neural Transmission, 2012, 119, 373-380.	1.4	14
96	Diffusion tensor imaging in the characterization of multiple system atrophy. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2181-2187.	1.0	13
97	Basal Ganglia Neuronal Activity during Scanning Eye Movements in Parkinsonâ€™s Disease. PLoS ONE, 2013, 8, e78581.	1.1	13
98	http://www.csnn.eu/en/czech-slovak-neurology-article/validity-study-of-the-boston-naming-test-czech-version-58260 Ceska A Slovenska Neurologie A Neurochirurgie, 2016, 79/112, 307-316.	0.0	13
99	WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia. Parkinsonism and Related Disorders, 2022, 94, 54-61.	1.1	13
100	Clinimetric validity of the Trail Making Test Czech version in Parkinsonâ€™s disease and normative data for older adults. Clinical Neuropsychologist, 2017, 31, 42-60.	1.5	12
101	Motion and emotion: anxietyâ€“axial connections in Parkinsonâ€™s disease. Journal of Neural Transmission, 2017, 124, 369-377.	1.4	12
102	Doseâ€Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. PM and R, 2018, 10, 1-10.	0.9	12
103	Variants in Mitochondrial <scp>ATP</scp> Synthase Cause Variable Neurologic Phenotypes. Annals of Neurology, 2022, 91, 225-237.	2.8	12
104	Brain stem auditory evoked potentials reflect central nervous system involvement in myasthenia gravis. Journal of Neurology, 1996, 243, 547-550.	1.8	11
105	A parsimonious scoring and normative calculator for the Parkinsonâ€™s disease mild cognitive impairment battery. Clinical Neuropsychologist, 2017, 31, 1231-1247.	1.5	11
106	Ataxia Telangiectasia Gene Mutation in Isolated Segmental Dystonia Without Ataxia and Telangiectasia. Movement Disorders Clinical Practice, 2018, 5, 89-91.	0.8	11
107	Clinical course of patients with pantothenate kinase-associated neurodegeneration (PKAN) before and after DBS surgery. Journal of Neurology, 2019, 266, 2962-2969.	1.8	11
108	Quantitative brain MR imaging in amyotrophic lateral sclerosis. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 67-76.	1.1	10

#	Article	IF	Citations
109	Motor Matters: Tackling Heterogeneity of Parkinsonâ€™s Disease in Functional MRI Studies. PLoS ONE, 2013, 8, e56133.	1.1	10
110	Disease-Specific Regions Outperform Whole-Brain Approaches in Identifying Progressive Supranuclear Palsy: A Multicentric MRI Study. Frontiers in Neuroscience, 2017, 11, 100.	1.4	10
111	Disentangling brain functional network remodeling in corticobasal syndrome â€“ A multimodal MRI study. NeuroImage: Clinical, 2020, 25, 102112.	1.4	10
112	Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. Frontiers in Neurology, 2021, 12, 646841.	1.1	10
113	Tremor magnitude: A single index to assess writing and drawing in essential tremor. Parkinsonism and Related Disorders, 2007, 13, 250-253.	1.1	9
114	Accounting for Movement Increases Sensitivity in Detecting Brain Activity in Parkinson's Disease. PLoS ONE, 2012, 7, e36271.	1.1	9
115	Benefits of pallidal stimulation in dystonia are linked to cerebellar volume and cortical inhibition. Scientific Reports, 2018, 8, 17218.	1.6	9
116	Severe paroxysmal dyskinesias without epilepsy in a RHOBTB2 mutation carrier. Parkinsonism and Related Disorders, 2020, 77, 87-88.	1.1	9
117	Dystonia as a prominent presenting feature in developmental and epileptic encephalopathies: A case series. Parkinsonism and Related Disorders, 2021, 90, 73-78.	1.1	9
118	Functional Imaging of Deep Brain Stimulation: fMRI, SPECT, and PET. , 2008, , 179-201.		9
119	Pallidal stimulation in dystonia affects cortical but not spinal inhibitory mechanisms. Journal of the Neurological Sciences, 2016, 369, 19-26.	0.3	8
120	Asymmetry of the insulaâ€sensorimotor circuit in Parkinson's disease. European Journal of Neuroscience, 2021, 54, 6267-6280.	1.2	8
121	Genetic overlap between dystonia and other neurologic disorders: A study of 1,100 exomes. Parkinsonism and Related Disorders, 2022, 102, 1-6.	1.1	8
122	Dualistic effect of pallidal deep brain stimulation on motor speech disorders in dystonia. Brain Stimulation, 2018, 11, 896-903.	0.7	7
123	Brief Visuospatial Memory Test-Revised: normative data and clinical utility of learning indices in Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2020, 42, 1099-1110.	0.8	7
124	A Recurrent <scp>VPS16</scp> p.Arg187* Nonsense Variant in Earlyâ€Onset Generalized Dystonia. Movement Disorders, 2021, 36, 1984-1985.	2.2	7
125	Scoring Algorithmâ€Based Genomic Testing in Dystonia: A Prospective Validation Study. Movement Disorders, 2021, 36, 1959-1964.	2.2	7
126	When can maximal efficacy occur with repeat botulinum toxin injection in upper limb spastic paresis?. Brain Communications, 2021, 3, fcaa201.	1.5	7

#	Article	IF	Citations
127	Identification of Microrecording Artifacts with Wavelet Analysis and Convolutional Neural Network: An Image Recognition Approach. Measurement Science Review, 2019, 19, 222-231.	0.6	7
128	Tremor associated with similar structural networks in Parkinson's disease and essential tremor. Parkinsonism and Related Disorders, 2022, 95, 28-34.	1.1	7
129	Optimization of Parkinson Disease treatment combining anti-Parkinson drugs and deep brain stimulation using patient diaries. , 2015, 2015, 3444-7.		6
130	Altered sensorimotor fMRI directed connectivity in Parkinson's disease patients. European Journal of Neuroscience, 2021, 53, 1976-1987.	1.2	6
131	Variant recurrence confirms the existence of a FBXO31â€related spasticâ€dystonic cerebral palsy syndrome. Annals of Clinical and Translational Neurology, 2021, 8, 951-955.	1.7	6
132	Symptom-severity-related brain connectivity alterations in functional movement disorders. NeuroImage: Clinical, 2022, 34, 102981.	1.4	6
133	A Loud Auditory Stimulus Overcomes Voluntary Movement Limitation in Cervical Dystonia. PLoS ONE, 2012, 7, e46586.	1.1	5
134	Topography of emotional valence and arousal within the motor part of the subthalamic nucleus in Parkinsonâ€™s disease. Scientific Reports, 2019, 9, 19924.	1.6	5
135	Validation of the Freezing of Gait Questionnaire in patients with Parkinsonâ€™s disease treated with deep brain stimulation. Neurological Sciences, 2020, 41, 1133-1138.	0.9	5
136	SERIALâ€ORDER recall in working memory across the cognitive spectrum of Parkinsonâ€™s disease and neuroimaging correlates. Journal of Neuropsychology, 2021, 15, 88-111.	0.6	5
137	Brittle Biballismâ€Dystonia in a Pediatric Patient with <scp>GNAO1</scp> Mutation Managed Using Pallidal Deep Brain Stimulation. Movement Disorders Clinical Practice, 2021, 8, 153-155.	0.8	5
138	A Neurodevelopmental Disorder With Dystonia and Chorea Resulting From Clustering <scp>CAMK4</scp> Variants. Movement Disorders, 2021, 36, 520-521.	2.2	5
139	Reply: fMRI during deep brain stimulation. Movement Disorders, 2003, 18, 461-462.	2.2	4
140	Supervised segmentation of microelectrode recording artifacts using power spectral density. , 2015, 2015, 1524-7.		4
141	Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training. Multiple Sclerosis and Related Disorders, 2021, 55, 103187.	0.9	4
142	Investigating network effects of DBS with fMRI. , 2022, , 275-301.		4
143	Reshaping cortical activity with subthalamic stimulation in Parkinson's disease during finger tapping and gait mapped by near infrared spectroscopy. Journal of Applied Biomedicine, 2019, 17, 157-166.	0.6	4
144	Improvement of active movement and function in adults with chronic spastic paresis following repeated treatment with abobotulinumtoxina (DysportÂ®). Toxicon, 2016, 123, S34-S35.	0.8	3

#	Article	IF	Citations
145	Recessive null-allele variants in MAG associated with spastic ataxia, nystagmus, neuropathy, and dystonia. Parkinsonism and Related Disorders, 2020, 77, 70-75.	1.1	3
146	Myoclonic dystonia phenotype related to a novel calmodulin-binding transcription activator 1 sequence variant. Neurogenetics, 2021, 22, 137-141.	0.7	3
147	Expiratory muscle strength training in Parkinson's disease patients: a pilot study of mobile monitoring application. Movement Disorders Clinical Practice, 2021, 8, 1148-1149.	0.8	3
148	3D visual cueing shortens the double support phase of the gait cycle in patients with advanced Parkinson's disease treated with DBS of the STN. PLoS ONE, 2020, 15, e0244676.	1.1	3
149	Bridging structural and functional biomarkers in functional movement disorder using network mapping. Brain and Behavior, 2022, 12, e2576.	1.0	3
150	Probabilistic Model of Neuronal Background Activity in Deep Brain Stimulation Trajectories. Lecture Notes in Computer Science, 2016, , 97-111.	1.0	2
151	Guided Self-rehabilitation Contracts Combined With AbobotulinumtoxinA in Adults With Spastic Paresis. Journal of Neurologic Physical Therapy, 2021, Publish Ahead of Print, 203-213.	0.7	2
152	Early manifestation of spasticity after first stroke in the territory of the internal carotid artery. A prospective multicenter study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2018, 162, 319-323.	0.2	2
153	SPG11: clinical and genetic features of seven Czech patients and literature review. Neurological Research, 2022, , 1-11.	0.6	2
154	The Instrumental Activities of Daily Living in Parkinsonâ€™s Disease Patients Treated by Subthalamic Deep Brain Stimulation. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
155	Microelectrode Neuronal Activity Biomarker of the Internal Globus Pallidus in Dystonia Correlates with Long-term Neuromodulation Effects. , 2018, , .		1
156	Cerebrospinal Fluid Leak to the IPG Subcutaneous Pocket after Deep Brain Stimulation Implantation: A Case Report. Stereotactic and Functional Neurosurgery, 2019, 97, 404-406.	0.8	1
157	Effect of pallidal deep-brain stimulation on articulation rate in dystonia. Neurological Sciences, 2019, 40, 869-873.	0.9	1
158	Trisomy X syndrome with dystonia and a pathogenic SATB1 variant. Neurological Sciences, 2021, 42, 3883-3884.	0.9	1
159	Electromagnetic field of mobile phones affects visual event related potential in patients with narcolepsy. Bioelectromagnetics, 2001, 22, 519-528.	0.9	1
160	The role of functional neuronavigation in the treatment of lesions in eloquent areas of the brain. International Congress Series, 2004, 1259, 389-395.	0.2	0
161	Acute Hyperkinetic Syndromes Treated with Stereotactic Neurosurgery Intervention â€“â€Š â€˙Three Case Reports. Ceska A Slovenska Neurologie A Neurochirurgie, 2015, 78/111, 591-596.	0.0	0
162	Comprehensive Care of Patients with Spastic Paresis â€“ A Long-Term Commitment. European Neurological Review, 2016, 11, 1b.	0.5	0

#	Article	IF	Citations
163	System for Motor Evoked Potentials Acquisition and Analysis. IFMBE Proceedings, 2019, , 87-91.	0.2	0
164	Progressive choreodystonia in Xâ€linked <scp>hyperâ€IgM</scp> immunodeficiency: a rare but recurrent presentation. Annals of Clinical and Translational Neurology, 2022, , .	1.7	0